These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 3661679)

  • 21. Lung injury secondary to chemotactic factor-induced leukocyte activation.
    Till GO; Ward PA
    Agents Actions Suppl; 1983; 12():383-96. PubMed ID: 6340440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eicosanoids are involved in the permeability changes but not the pulmonary hypertension after systemic activation of complement.
    Morganroth ML; Till GO; Schoeneich S; Ward PA
    Lab Invest; 1988 Mar; 58(3):316-23. PubMed ID: 2831433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of complement activation with cobra venom factor on pulmonary vascular permeability.
    Johnson A; Cooper JA; Malik AB
    J Appl Physiol (1985); 1986 Dec; 61(6):2202-9. PubMed ID: 3027023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Attenuation by 2,3-dihydroxybenzoic acid of acute lung injury induced by cobra venom factor in the rat.
    Baldwin SR; Simon RH; Boxer LA; Till GO; Kunkel RG
    Am Rev Respir Dis; 1985 Dec; 132(6):1288-93. PubMed ID: 4073669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mediators of lung injury in mice following systemic activation of complement.
    Tvedten HW; Till GO; Ward PA
    Am J Pathol; 1985 Apr; 119(1):92-100. PubMed ID: 3985125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hybrid proteins of Cobra Venom Factor and cobra C3: tools to identify functionally important regions in Cobra Venom Factor.
    Hew BE; Wehrhahn D; Fritzinger DC; Vogel CW
    Toxicon; 2012 Sep; 60(4):632-47. PubMed ID: 22609532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhaled asbestos activates a complement-dependent chemoattractant for macrophages.
    Warheit DB; George G; Hill LH; Snyderman R; Brody AR
    Lab Invest; 1985 May; 52(5):505-14. PubMed ID: 3990243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lung inflammation induced by complement-derived chemotactic fragments in the alveolus.
    Shaw JO; Henson PM; Henson J; Webster RO
    Lab Invest; 1980 May; 42(5):547-58. PubMed ID: 7382429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complement depletion with humanised cobra venom factor: efficacy in preclinical models of vascular diseases.
    Vogel CW; Fritzinger DC; Gorsuch WB; Stahl GL
    Thromb Haemost; 2015 Mar; 113(3):548-52. PubMed ID: 25031089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protective effects of soluble CR1 in complement- and neutrophil-mediated tissue injury.
    Mulligan MS; Yeh CG; Rudolph AR; Ward PA
    J Immunol; 1992 Mar; 148(5):1479-85. PubMed ID: 1311349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of systemic complement activation and neutrophil-mediated pulmonary injury on the retention and metastasis of circulating cancer cells in mouse lungs.
    Orr FW; Warner DJ
    Lab Invest; 1990 Mar; 62(3):331-8. PubMed ID: 2314052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutrophil-dependent, oxygen-radical mediated lung injury associated with acute pancreatitis.
    Guice KS; Oldham KT; Caty MG; Johnson KJ; Ward PA
    Ann Surg; 1989 Dec; 210(6):740-7. PubMed ID: 2589887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glomerular injury and proteinuria in rats after intrarenal injection of cobra venom factor. Evidence for the role of neutrophil-derived oxygen free radicals.
    Rehan A; Wiggins RC; Kunkel RG; Till GO; Johnson KJ
    Am J Pathol; 1986 Apr; 123(1):57-66. PubMed ID: 2421581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of complement in endotoxin/platelet-activating factor-induced lung injury.
    Rabinovici R; Yeh CG; Hillegass LM; Griswold DE; DiMartino MJ; Vernick J; Fong KL; Feuerstein G
    J Immunol; 1992 Sep; 149(5):1744-50. PubMed ID: 1324280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre-treatment of donor with 1-deamino-8-d-arginine vasopressin could alleviate early failure of porcine xenograft in a cobra venom factor treated canine recipient.
    Kang HJ; Lee G; Kim JY; Lee SH; Wi HC; Hwang PG; Chung DH; Kim YT
    Eur J Cardiothorac Surg; 2005 Jul; 28(1):149-56. PubMed ID: 15982598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Requirement and role of C5a in acute lung inflammatory injury in rats.
    Mulligan MS; Schmid E; Beck-Schimmer B; Till GO; Friedl HP; Brauer RB; Hugli TE; Miyasaka M; Warner RL; Johnson KJ; Ward PA
    J Clin Invest; 1996 Jul; 98(2):503-12. PubMed ID: 8755663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methionine modification impairs the C5-cleavage function of cobra venom factor-dependent C3/C5 convertase.
    Fu Q; McPhie P; Gowda DC
    Biochem Mol Biol Int; 1998 Jun; 45(1):133-44. PubMed ID: 9635137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion.
    Vogel CW; Fritzinger DC
    Curr Pharm Des; 2007; 13(28):2916-26. PubMed ID: 17979736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A new low molecular-weight protein effector of human complement from the venom of the Central Asian cobra Naja naja oxiana].
    Kozlov LV; Soliakov LS; Zinchenko AA
    Bioorg Khim; 1984 Mar; 10(3):323-32. PubMed ID: 6567467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of antigen-induced bronchoconstriction after intravascular complement activation with cobra venom factor. Reversal by granulocyte depletion.
    Regal JF; Fraser DG; Anderson DE; Solem LE
    J Immunol; 1993 Apr; 150(8 Pt 1):3496-505. PubMed ID: 8468484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.